No…
Phase 3 trial in sr-aGvHd in under 12’s …passed primary endpoints.CRL issued about CMC
Phase 3 trial in LVAD …….bleeding in the gut as secondary endpoint accepted by FDA
Phase 3 trial in CLBP …..endpoint in functionality missed but pain accepted in further confirmatory trial due to opiod addiction
Phase 3 trial in CHF …dream failed in hospitilisations but secondary endpoints in diabetecs accepted Now FDA is processing what is the next stage
IE if these 4 trials continue to another trial it is effectively a phase 4 trial
MSB 2022 - The road to commercialisation, page-1427
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
-0.025(1.86%) |
Mkt cap ! $1.507B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.35 | $1.31 | $2.699M | 2.040M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34995 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 10374 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |